v3.22.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating Expenses        
Research and development expenses $ 3,137,292 $ 1,614,954 $ 5,181,912 $ 3,086,401
Acquisition of in-process research and development 515,630 515,630
General and administrative expenses 2,034,456 1,329,213 3,218,550 2,051,073
Operating Loss (5,171,748) (3,459,797) (8,400,462) (5,653,104)
Other Income (Expense)        
Forgiveness of PPP loan and related accrued interest 163,771 163,771
Interest expense (362)
Interest income 7,380 1,814 8,963 6,755
Net Operating Loss Before Income Tax Benefit (5,164,368) (3,294,212) (8,391,499) (5,482,940)
Income Tax Benefit 137,169 226,417
Net Loss $ (5,164,368) $ (3,157,043) $ (8,391,499) $ (5,256,523)
Net Loss per Common Share - Basic and Diluted $ (0.32) $ (0.20) $ (0.53) $ (0.35)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted 15,940,510 15,406,363 15,886,116 14,997,303

Source